Contenido principal del artículo

Resumen

La infección por el SARS-CoV-2 (COVID-19) ha supuesto un importante impacto en la actividad trasplantadora en nuestro país. En su condición de paciente inmunodeprimido y con frecuentes comorbilidades, era esperable que la mortalidad y el riesgo de complicaciones asociadas a la COVID-19 en el receptor de trasplante renal (TR) fueran mayores en comparación con la población general, si bien la información al respecto en los primeros meses de la pandemia era muy limitada. Desde marzo de 2020 hemos mejorado rápidamente nuestro conocimiento acerca de la epidemiología, características clínicas y manejo de la COVID-19 post-trasplante. La presente revisión pretende recopilar la información disponible a julio de 2021 en respuesta a una serie de cuestiones relevantes: ¿cómo se manifiesta clínicamente la infección por SARS-CoV-2 en receptores de TR?, ¿cuáles son sus factores pronósticos?, ¿es más grave la COVID-19 en el contexto del TR respecto a los pacientes inmunocompetentes?, ¿de qué opciones de tratamiento antiviral disponemos actualmente para el receptor de TR?, ¿cuál es la experiencia disponible con los tratamientos inmunomoduladores? y, por último, ¿son eficaces las vacunas frente a la COVID-19 basadas en ARN mensajero en esta población?. A pesar de los avances realizados aún son varios los aspectos que debemos mejorar en nuestro abordaje de la infección por SARS-CoV-2 en el ámbito específico del TR.

Palabras clave

Covid-19 trasplante renal epidemiología presentación clínica pronóstico tratamiento vacunación SARS-CoV-2

Detalles del artículo

Cómo citar
1.
Fernández-Ruiz M. COVID-19 en receptores de trasplante renal: ¿qué hemos aprendido tras 18 meses de pandemia?. Enferm Nefrol [Internet]. 30 de septiembre de 2021 [citado 29 de noviembre de 2021];24(3):219-31. Disponible en: https://www.enfermerianefrologica.com/revista/article/view/4403

Datos de los fondos

Referencias

  1. Domínguez-Gil B, Coll E, Fernández-Ruiz M, Del Rio F, Zaragoza R, Rubio JJ, et al. COVID-19 in Spain: Transplantation in the midst of the pandemic. Am J Transplant. 2020;20(9):2593-8.
  2. Azzi Y, Parides M, Alani O, Loarte-Campos P, Bastarsh R, Forest S, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 2020;98(6):1559-67.
  3. Crespo M, Mazuecos A, Rodrigo E, Gavela E, Villanego F, Sánchez-Álvarez E, et al. Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients. Transplantation. 2020;104(11):2225-33.
  4. Oto OA, Ozturk S, Turgutalp K, Arici M, Alpay N, Merhametsiz O, et al. Predicting the outcome of COVID-19 infection in kidney transplant recipients. BMC Nephrol. 2021;22(1):100.
  5. Kute VB, Bhalla AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al. Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study From India. Transplantation. 2021;105(4):851-60.
  6. Pierrotti LC, Reusing Junior JO, Freire MP, Barros-Machado DJ, Megale-Moreira R, Ventura CG, et al. COVID-19 among kidney-transplant recipients requiring hospitalization: preliminary data and outcomes from a single-center in Brazil. Transpl Int. 2020;33(12):1837-42.
  7. Caillard S, Anglicheau D, Matignon M, Durrbach A, Greze C, Frimat L, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020;98(6):1549-58.
  8. Fava A, Cucchiari D, Montero N, Toapanta N, Centellas FJ, Vila-Santandreu A, et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. Am J Transplant. 2020;20(11):3030-41.
  9. Guill´´en E, Pineiro GJ, Revuelta I, Rodríguez D, Bodro M, Moreno A, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant. 2020;20(7):1875-8.
  10. Elias M, Pievani D, Randoux C, Louis K, Denis B, Delion A, et al. COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. J Am Soc Nephrol. 2020;31(10):2413-23.
  11. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. COVID-19 in solid organ transplant: A multi-center cohort study. Clin Infect Dis. 2020. [En prensa]. DOI: https://doi.org/10.1093/cid/ciaa1097
  12. Coll E, Fernández-Ruiz M, Padilla M, Moreso F, Hernández-Vicente A, Yañez I, et al. COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave? Transplantation. 2021. [En prensa]. DOI: https://doi.org/10.1097/TP.0000000000003873.
  13. García-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83-8.
  14. Trujillo H, Fernández-Ruiz M, Gutiérrez E, Sevillano A, Caravaca-Fontán F, Morales E, et al. Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. Transpl Infect Dis. 2021;23(2):e13501.
  15. Cruzado Vega LL, Santos García A. SARS-CoV-2 and Aspergillus pneumonia in kidney transplantation: More frequent than we think? Nefrologia (Engl Ed). 2021.
  16. Arana C, Cuevas Ramírez RE, Xipell M, Casals J, Moreno A, Herrera S, et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. Transpl Infect Dis. 2021:e13652.
  17. Skonieczny P, Heleniak Z, Szostakiewicz M, Kuziemski K, Debska-Slizien A. Coinfection of COVID-19 and pneumocystosis in a patient after kidney transplantation. Pol Arch Intern Med. 2021;131(6):566-7.
  18. Benotmane I, Risch S, Doderer-Lang C, Caillard S, Fafi-Kremer S. Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. Am J Transplant. 2021.
  19. Italiano J, Bush R, Acharya R, Upadhyay K. Persistent viral shedding despite seroconversion in a kidney transplant recipient with severe extrapulmonary COVID-19. BMJ Case Rep. 2020;13(11).20.
  20. Kremer D, Pieters TT, Verhaar MC, Berger SP, Bakker SJL, van Zuilen AD, et al. A Systematic Review and Meta-analysis of COVID-19 in Kidney Transplant Recipients: Lessons to be Learned. Am J Transplant. 2021. [En prensa].
  21. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez E, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540-8.
  22. Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, et al. COVID-19 related mortality in kidney transplant and hemodialysis patients: a comparative, prospective registry based study. Nephrol Dial Transplant. 2021.
  23. Clarke C, Lucisano G, Prendecki M, Gleeson S, Martin P, Ali M, et al. Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. Kidney Int Rep. 2021;6(1):46-55.
  24. Mahalingasivam V, Craik A, Tomlinson LA, Ge L, Hou k, Wang Q, et al. A Systematic Review of COVID-19 and Kidney Transplantation. Kidney Int Rep. 2021;6(1):24-45.
  25. Villanego F, Mazuecos A, Pérez-Flores IM, Moreso F, Andrés A, Jiménez-Martín C, et al. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. Am J Transplant. 2021;21(7):2573-82.
  26. Gutiérrez-Gutiérrez B, Del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, et al. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infect Dis. 2021;21(6):783-92.
  27. Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, et al. COVID-19 and kidney transplantation:Results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140-8.
  28. Salto-Alejandre S, Jiménez-Jorge S, Sabe N, Ramos-Martínez A, Linares L, Valerio M, et al. Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. PLoS One. 2021;16(4):e0250796.
  29. Bajpai D, Deb S, Bose S, Gandhi C, Modi T, Katyal A, et al. Recovery of kidney function after AKI because of COVID-19 in kidney transplant recipients. Transpl Int. 2021;34(6):1074-82.
  30. Elec AD, Oltean M, Goldis P, Cismaru C, Lupse M, Muntean A, et al. COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment. Int J Infect Dis. 2021;104:426-32.
  31. Van Delden C. Is transplantation per se a risk factor for worse outcome of SARS-CoV-2 infection in kidney transplant recipients? Transpl Int. 2021;34(5):775-7.32.
  32. Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis. Am J Transplant. 2020;20(7):1947-8.
  33. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021;384(8):693-704.
  34. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499–518.
  35. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Chazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19. N Engl J Med. 2021;384(9):795-807.
  36. Miarons M, Larrosa-García M, García-García S, Los-Arcos I, Moreso F, Berastegui C, et al. COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management. Transplantation. 2021;105(1):138-50.
  37. Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21(3):1295-303.
  38. Hadi YB, Naqvi SFZ, Kupec JT, Sofka S, Sarwari A. Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network. Transplantation. 2021;105(6):1365-71.
  39. Chavarot N, Gueguen J, Bonnet G, Jdidou M, Trimaille A, Burger C, et al. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. Am J Transplant. 2021;21(3):1285-94.
  40. Sharma P, Chen V, Fung CM, Troost JP, Patel VN, Combs M, et al. COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study. Transplantation. 2021;105(1):128-37.
  41. Fisher AM, Schlauch D, Mulloy M, Dao A, Reyad AI, Correl M, et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin Transplant. 2021;35(4):e14216.
  42. Nair V, Jandovitz N, Hirsch JS, Abate M, Satapathy SK, Roth N, Miyara SJ, et al. An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. Am J Transplant. 2021;21(7):2522-31.
  43. Pawar AY. Combating devastating COVID-19 by drug repurposing. Int J Antimicrob Agents. 2020;56(2):105984.
  44. Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Türler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 2004;10(7):939-44.
  45. Fernández-Ruiz M, Andres A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020;20(7):1849-58.
  46. Xia T, Wang Y. Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome. Am J Transplant. 2020;20(9):2630-1.
  47. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2021;21(5):1825-37.
  48. Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for COVID-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511.
  49. Group RC. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605-12.
  50. Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020.
  51. Group RC, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. N Engl J Med. 2020;383(21):2030-40.
  52. Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2021.
  53. Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of Pharmacology, Preclinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020;40(7):659-71.
  54. Beigel JH, Tomashek KM, Dodd LE, Mehta A, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of COVID-19 - Final Report. N Engl J Med. 2020;383(19):1813-26.
  55. Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, et al. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial. Ann Intern Med. 2021.
  56. Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Pascual J, Crespo M. Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney Int Rep. 2021.
  57. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao J, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. N Engl J Med. 2021;384(3):238-51.
  58. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19. N Engl J Med. 2021.
  59. Dhand A, Lobo SA, Wolfe K, Feola N, Lee L, Nog R, et al. Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience. Transplantation. 2021;105(7):e68-e9.
  60. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537.
  61. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-73.
  62. Fernández-Ruiz M, López-Medrano F, Aguado JM. Tocilizumab for the treatment of COVID-19. Expert Opin Biol Ther. 2021;21(4):431-4.
  63. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-45.
  64. REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N Engl J Med. 2021;384(16):1491-502.
  65. Mariette X, Hermine O, Tharaux PL, Resche-Rigon M, Steg PG, Porcher R, et al. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Intern Med. 2021.
  66. Fernández-Ruiz M, Aguado JM. Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. Curr Transplant Rep. 2020:1-11.
  67. Guella A, Elfadil O, Abdulrazaq G, Osman S, Khan MM, Ahmed A, et al. Favorable Outcome of COVID-19 Pneumonia in a Kidney Transplant Recipient Treated with Tocilizumab. Case Rep Infect Dis. 2020;2020:8830626.
  68. Trujillo H, Caravaca-Fontán F, Sevillano A, Gutiérrez E, Fernández-Ruiz M, López Medrano F, et al. Tocilizumab use in Kidney Transplant Patients with COVID-19. Clin Transplant. 2020;34(11):e14072.
  69. Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, Ventura-Agujar P, Bada-Bosch T, Pérez-Flores I, et al. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant. 2020;20(11):3182-90.
  70. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
  71. Ringer M, Azmy V, Kaman K, Tang D, Cheung H, Azar M, et al. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients. Transpl Infect Dis. 2021;23(2):e13556.
  72. Pereira MR, Aversa MM, Farr MA, Miko FA, Aaron JG, Mohan S, et al. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. Am J Transplant. 2020;20(11):3198-205.
  73. Bodro M, Cofan F, Rios J, Herrera S, Linares L, Marcos MA, et al. Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19. J Clin Med. 2021;10(8).
  74. Pulakurthi YS, Pederson JM, Saravu K, Gupta N, Balasubramanian P, Kamrowski S, et al. Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(20):e25719.
  75. Karruli A, Spiezia S, Boccia F, Gagliardi M, Patauner F, Salemme A, et al. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis. Transpl Infect Dis.2021:e13595.
  76. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of COVID-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021.
  77. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
  78. Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21(8):2727-39.
  79. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325(21):2204-6.
  80. Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. Am J Transplant. 2021;21(8):2916-8.
  81. Ali NM, Alnazari N, Mehta SA, Boyarsky B, Avery RK, Segev DL, et al. Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. Transplantation. 2021;105(9):e104-6.
  82. Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27(8):1173.e1-1173.e4.
  83. Baluch A, Humar A, Eurich D, Egli A, Liacini A, Hoschler K, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13(4):1026-33.
  84. Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Sashar M, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719-26.
  85. Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral Response after SARS-CoV-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. J Am Soc Nephrol. 2021;32(9):2153-8.
  86. Chavarot N, Ouedrani A, Marion O, Leruez-Ville M, Vilain E, Baaziz M, et al. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. Transplantation. 2021;105(9):e94-5.
  87. Ou MT, Boyarsky BJ, Chiang TPY, Bae S, Werbel WA, Avery RK, et al. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation. 2021;105(9):2119-23.
  88. Benotmane I, Gautier-Vargas G, Gallais F, Gantner P, Cognard N, Olagne J, et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. Am J Transplant. 2021. [en prensa]. DOI: https://doi.org/10.1111/ajt.16764.
  89. Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, et al. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021. [en prensa].
  90. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA COVID-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021;385:661-2.
  91. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang J, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021;174:1330-2.
  92. Mamode N, Ahmed Z, Jones G, Banga N, Motallebzadeh R, Tolley H, et al. Mortality Rates in Transplant Recipients and Transplantation Candidates in a High-prevalence COVID-19 Environment. Transplantation. 2021;105(1):212-5.
  93. Al Otaibi TM, Gheith OA, Abuelmagd MM, Adel M, Alqallaf AK, Elserwy NA et al. Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. Clin Transplant. 2021;35(6):e14297.
  94. Alshaqaq A, Al Abadi A, Altheaby A, Bukhari M, Alnasrallah B, Alamoudi A, et al. Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities. Ann Transplant. 2021;26:e931832.
  95. Caillard S, Chavarot N, Francois H, Matignon M, Snanoudj R, Tourret J, et al. Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients. Kidney Int Rep. 2021. [en prensa]. doi: 10.1016/j.ekir.2021.06.034.